Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Cotavance Drug-Eluting Balloon (DEB) Catheter

A paclitaxel-eluting balloon catheter for the minimally invasive treatment of peripheral artery obstruction in patients who require angioplasty of the femoropopliteal arteries. 

Dior Drug-Eluting Balloon (DEB) Catheter

A paclitaxel-eluting balloon catheter for treatment of coronary in-stent restenosis, bifurcated coronary artery lesions, and lesions in small-diameter coronary arteries.

Zaltrap (ziv-aflibercept)

An intravenous antivascular endothelial growth factor agent for second-line treatment of metastatic colorectal cancer.

Stivarga for Gastrointestinal Stromal Tumors

An oral multikinase inhibitor for the third-line treatment of metastatic and/or unresectable gastrointestinal stromal tumors in patients whose disease has progressed despite prior treatment.